findmyKOL
Clinical trialNCT02151981CompletedPhase 3Interventional

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

SponsorAstraZenecaEnrollment421Anticancer Treatment
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Vassiliki A Papadimitrakopoulou, MD

    The University of Texas/M.D. Anderson Cancer Center, Houston, Tx, USA

    Principal Investigator
  • Yilong Wu, MD

    Guangdong General Hospital, Guangdong, 510030, China

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

150 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Research Site

    Darlinghurst, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Woolloongabba, Australia

Canada
  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

China
  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Nanchang, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Tianjin, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Ürümqi, China

France
  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Dijon, France

  • Research Site

    Lille, France

  • Research Site

    Marseille, France

  • Research Site

    Paris, France

  • Research Site

    Strasbourg, France

  • Research Site

    Toulouse, France

  • Research Site

    Villejuif, France

Germany
  • Research Site

    Essen, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Gerlingen, Germany

  • Research Site

    Oldenburg, Germany

  • Research Site

    Regensburg, Germany

110 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Aug 2014
Primary completion
15 Apr 2016
Completion
15 Dec 2023
Last update posted
7 Jan 2025
Registered enrollment
421
Registry id
NCT02151981

Cross-registrations

EU-CTR / CTIS (EudraCT)2014-000594-39

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.